Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Denosumab × Thoracic × Clear all

Phase

Phase 2 3 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 9 Breast 9 Plasma cell 4 Thoracic 1 Sarcoma 1 Other solid neoplasm 1 Other hematologic neoplasm 1 Myeloid 1 Lymphoid 1 Head & Neck 1 Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 282 Cisplatin 225 Pemetrexed 196 Paclitaxel 151 Docetaxel 130 pembrolizumab 108 Gemcitabine 94 Etoposide 63 Erlotinib Hydrochloride 59 Radiotherapy 54 Vinorelbine 47 Gefitinib 46 Bevacizumab 46 durvalumab 45 atezolizumab 41 Nivolumab 39 Drug Therapy 34 osimertinib 30 Topotecan 29 tislelizumab 23 130-nm albumin-bound paclitaxel 23 Radiosurgery 20 Ipilimumab 18 Crizotinib 18 Magnetic Resonance Spectroscopy 15 Albumin-Bound Paclitaxel 15 Surgical Procedures, Operative 14 aumolertinib 13 Platinum 13 Injections 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02129699 2024-09-19

SPLENDOUR

ETOP IBCSG Partners Foundation

Phase 3 Terminated

595 enrolled 18 charts

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡